Gyre Therapeutics, Inc. GYRE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.52M+2.1% | $37.2M+33.4% | $30.56M+19.9% | $26.77M+6.1% | $22.06M-18.8% | ||
| $1.23M+37.2% | $1.74M+48.1% | $1.63M+69.9% | $1.15M+49.5% | $894K-8.7% | ||
| $21.29M+0.6% | $35.45M+32.8% | $28.94M+18.0% | $25.62M+4.8% | $21.16M-19.2% | ||
| 94.6%-1.4pp | 95.3%-0.5pp | 94.7%-1.6pp | 95.7%-1.2pp | 95.9%-0.4pp | ||
| $6.74M+118% | $4.82M+29.7% | $2.36M-14.8% | $3.43M+2.1% | $3.1M+41.8% | ||
| $14.14M+30.4% | $23.82M+41.3% | $15.33M+11.9% | $15.19M+5.4% | $10.84M-13.6% | ||
| $7.22M+45.7% | $6.7M+22.6% | $4.32M+13.0% | $4.83M+41.0% | $4.96M+45.8% | ||
| $31.87M+61.1% | $37.08M+36.3% | $23.64M+11.2% | $24.6M+11.7% | $19.79M+3.6% | ||
| -$9.36M-512% | $118K-82.3% | $6.93M+63.6% | $2.17M-32.0% | $2.27M-71.8% | ||
| -41.5%-51.8pp | 0.3%-2.1pp | 22.7%+6.0pp | 8.1%-4.6pp | 10.3%-19.4pp | ||
| $29K-72.9% | -$2.19M-34.3% | $727K+1,069% | -$145K-101% | $107K-12.3% | ||
| -$9.24M-299% | $0-100% | $7.63M+94.1% | $2.24M-62.9% | $4.64M-62.9% | ||
| $621K-31.1% | $1.3M+540% | $1.69M+57.6% | $662K-55.8% | $901K-64.6% | ||
| -$8.69M-422% | —— | $3.61M+221% | $442K-87.5% | $2.7M-64.2% | ||
| -38.6%-50.8pp | —— | 11.8%+7.4pp | 1.7%-12.3pp | 12.2%-15.5pp | ||
| -$0.10— | —— | $0.03+200% | $0.00-100% | $0.00-100% | ||
| -$0.10-433% | —— | $0.04+300% | $0.00-100% | $0.03-66.7% | ||
| 91.3M-10.4% | 103.2M+0.9% | 104M+1.3% | 102.7M+0.5% | 102M-0.6% | ||
| 91.3M+5.7% | 89.3M+5.0% | 90.9M+6.1% | 89.1M+4.2% | 86.4M+3.8% | ||
| $2.55M— | —— | —— | —— | —— | ||
| -$7.33M-361% | —— | $4.2M+91.9% | $641K-80.3% | $2.81M-62.2% | ||
| -$16K— | -$2K+87.9% | -$1K+93.9% | —— | —— | ||
| $29K-72.9% | -$2.19M-34.3% | $727K+1,069% | -$145K-101% | $107K-12.3% | ||
| $22.52M+2.1% | $37.2M+33.4% | $30.56M+19.9% | $26.77M+6.1% | $22.06M-18.8% | ||
| -$9.36M-512% | $118K-82.3% | $6.93M+63.6% | $2.17M-32.0% | $2.27M-71.8% | ||
| -$8.68M-409% | $774K-31.3% | $7.57M+61.9% | $2.81M-17.8% | $2.81M-66.9% | ||
| -$8.68M-409% | $774K-31.3% | $7.57M+61.9% | $2.81M-17.8% | $2.81M-66.9% | ||
| -38.6%-51.3pp | 2.1%-2.0pp | 24.8%+6.4pp | 10.5%-3.1pp | 12.7%-18.5pp | ||
| -$9.36M-512% | $118K-82.3% | $6.93M+63.6% | $2.17M-32.0% | $2.27M-71.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gyre Therapeutics, Inc.'s revenue?
- Gyre Therapeutics, Inc. (GYRE) generated $117.0M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Gyre Therapeutics, Inc. profitable?
- Gyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $1.9M over the trailing twelve months, a 6.3% net margin.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gross margin is 95.1% and operating margin is -0.1%, with a 6.3% net margin.
- What is Gyre Therapeutics, Inc.'s earnings per share?
- Gyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.07.
- Where does Gyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
